Navigation Links
Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel,Anticancer Agents, at AACR

HAYWARD, Calif., April 18, 2007 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated today presented preclinical data on its proprietary nuclear export inhibitors (NEI) showing induction of potent, fast-acting and long-lasting anticancer activity with a high degree of tolerability in multiple human tumor xenograft cancer models.

Kosan's NEIs are potent, specific inhibitors of CRM1, a highly conserved, essential protein that exports key regulatory proteins ("cargo" proteins) from the nucleus to the cytoplasm. Many cargo proteins that depend on CRM1 for nuclear export, such as p53, Bcr-Abl and FOXO-3a, function as tumor suppressors or transcription factors that protect normal cells by regulating cell growth and apoptosis (cell death). Accumulation of these CRM1 cargo proteins in the nucleus, by blocking nuclear export, leads to the inhibition of cell growth and apoptosis selectively in cancer cells. Kosan's polyketide- based NEI compounds have optimized pharmaceutical properties, including potency, durability of action and a wide therapeutic index. Kosan anticipates becoming the first company to advance a nuclear export inhibitor into clinical development.

"We believe that Kosan has established an industry-leading position in NEI technology and has the only NEI inhibitor in late-stage preclinical development," said Pieter B.M.W.M. Timmermans, Ph.D., Kosan's Senior Vice President, Drug Discovery and Preclinical Development. "Our NEIs have demonstrated potent anticancer activity in human tumor xenograft models of breast, cervical, colon and non-small cell lung cancers, melanoma and leukemia, and have been shown to have robust efficacy in vivo at doses that are well-tolerated. We believe that NEIs represent a novel mechanism of action and have the potential to work additively and synergistically with a broad spectrum of cancer chemotherapies such as DNA-damaging agents that have limited durability
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
6. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
7. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
Post Your Comments:
(Date:3/27/2015)... XRpro Sciences, Inc., a provider of ... services which features high throughput transporter and ion ... results for the year ended December 31, 2014. ... XRpro Sciences commented, "We have completed a number ... to commercial stage in large part by achieving ...
(Date:3/27/2015)... -- Report Details  New study ... What does the future hold for top ... brand new report shows you potential revenues to 2025, ... Our 242-page report provides 185 tables, charts, and graphs. ... the future market prospects. Our new study lets you ...
(Date:3/27/2015)... -- According to a new market research ... Ultrasound), Ablation Catheter (Cryoablation, RF, Microwave), Lab Devices (Mapping, ... - Global Forecasts to 2019 ", published by MarketsandMarkets, the ... Billion by 2019 with a CAGR of around 10.3% ... Browse   90   ma rket data ...
Breaking Medicine Technology:XRpro Sciences Announces Fiscal 2014 Financial Results 2XRpro Sciences Announces Fiscal 2014 Financial Results 3XRpro Sciences Announces Fiscal 2014 Financial Results 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 2Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 3Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 5Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 6Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 7Electrophysiology (EP) Market Worth $4.73 Billion by 2019 2Electrophysiology (EP) Market Worth $4.73 Billion by 2019 3Electrophysiology (EP) Market Worth $4.73 Billion by 2019 4
... 2011 US-based Life Technologies Corporation (Nasdaq: ... science solutions, announced today that it has launched a ... demand in the Asia Pacific regions of India, China, ... New Zealand. (Logo:   http://photos.prnewswire.com/prnh/20110216/MM49339LOGO ) ...
... GlaxoSmithKline (NYSE: GSK ) today announced that ... full approval for PROMACTA® (eltrombopag), an oral tablet that ... blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP) who ... splenectomy. PROMACTA initially received FDA orphan ...
Cached Medicine Technology:Life Technologies Launches Asia Distribution Center in Singapore 2Life Technologies Launches Asia Distribution Center in Singapore 3Life Technologies Launches Asia Distribution Center in Singapore 4FDA Grants Full Approval for PROMACTA® (eltrombopag) for Treatment of Rare Blood Disorder 2FDA Grants Full Approval for PROMACTA® (eltrombopag) for Treatment of Rare Blood Disorder 3FDA Grants Full Approval for PROMACTA® (eltrombopag) for Treatment of Rare Blood Disorder 4
(Date:3/29/2015)... March 29, 2015 “Health is an ... as we learn more about the cannabinoid system … ... March Homeostasis: Publius’ Go Endo-Cannabinoid Update ~ new ... endo-healing, is celebrated. Publius, of The Cannabis Papers: A ... Institutes of Health (PubMed) cannabinoid system (CS) articles discussing: ...
(Date:3/28/2015)... Could genetic code determine someone’s coffee ... by researchers at the Harvard T.H. Chan School ... of the Coffee and Caffeine Genetics Consortium and ... fall, the study—one of several recent HSPH investigations of ... more than 120,000 regular coffee drinkers of European and ...
(Date:3/28/2015)... 28, 2015 With more than ... fields of osteoporosis, osteoarthritis and musculoskeletal diseases gathered ... may be the first time in the 17-year ... that the hot-button topic is an emerging non-pharmaceutical ... well-accepted scientific principles of Wolff’s law, osteogenic loading ...
(Date:3/28/2015)... March 28, 2015 Emergency Medical Care ... care in Manhattan, recently commemorated its three-year anniversary of ... Manhattan. In addition to 24-hour urgent care, Emergency Medical ... , At this time, Emergency Medical Care’s Urgent ... asthma, chest pain, eye injuries, ear infections, fevers, insect ...
(Date:3/28/2015)... Chicago, IL (PRWEB) March 28, 2015 Centurion ... medical equipment auction on Thursday, April 2 at their Las ... Las Vegas, NV 89081. The sale, which consists of equipment ... will begin promptly at 9 a.m. PDT. , Buyers ... radiology and surgery equipment. “We are a one-stop-shop,” said Erik ...
Breaking Medicine News(10 mins):Health News:March Homeostasis: Publius’ Go Endo-Cannabinoid Update ~ New on the Bryan William Brickner Blog 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 3Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:Emergency Medical Care Celebrates Three Years of 24/7 Walk-In Urgent Care Services 2Health News:Medical Equipment Auction to Take Place in North Las Vegas 2
... Fla., Feb. 26 John Williams,a shrimp fisherman ... today before the House Subcommittee on Oversight and,Investigations ... safety. Williams criticized the Food and Drug Administration,s,(FDA) ... recommended Congress,take legislative actions., "On behalf of ...
... Customers and ... Private Insurance Corporations, OAKLAND, Calif., Feb. 26 ... organized by the California,Nurses Association/National Nurses Organizing Committee that ... a,9/11 rescue worker; Donna Smith, who has recently joined ...
... 690, Hospital Reach Settlement on Outstanding Disputes, ... General Hospital in Sandpoint, Idaho reached settlement on ... of Local 690,in Spokane, Washington., "This settlement ... to,perform their jobs capably despite management,s refusal to ...
... connects, educates and entertains sports world, KANSAS ... a new,online hotspot with Kansas City roots. A ... produce AthletixNation.com, the premier,community for all athletes, fans, ... AthletixNation.com is to have a positive impact,on the ...
... announces the release,of two new lifts, and a campaign ... open, twin mast design, and the SARA Lite, a ... twin masts, which improve stability and weight,distribution, but also ... functions, including Powered DPS (Dynamic Positioning System),are controlled via ...
... - Michel de Rosen to Continue as Chairman of the Board ... B. Soland Promoted to Chief Operating Officer -, ... announced today that, effective March 31, 2008, Vincent J.,Milano will succeed ... and has been elected to its board of directors. Mr.,de Rosen, ...
Cached Medicine News:Health News:Testimony to Congress Denounces FDA Reliance on Self-Policing 2Health News:Michael Moore Defends 9/11 Rescue Workers and Criticizes Insurance Industry on California Nurses Association Press Call 2Health News:Nurses Convince Hospital to Return to Bargaining Table 2Health News:AthletixNation.com Launches Sports Website and Community Programs 2Health News:Vincent J. Milano to Succeed Michel de Rosen as President and Chief Executive Officer of ViroPharma 2Health News:Vincent J. Milano to Succeed Michel de Rosen as President and Chief Executive Officer of ViroPharma 3
... (IGF-II) is a 7.5 kDa peptide which is ... to have mitogenic and metabolic actions involved in ... by binding to target cell receptors. IGF-II binds ... receptor, a monomeric protein which also serves as ...
... growth factor II (IGF-II) is a 7.5 kDa ... and is postulated to have mitogenic and metabolic ... IGF-II are mediated by binding to target cell ... Type II IGF receptor, a monomeric protein which ...
... growth factor II (IGF-II) is a 7.5 kDa ... and is postulated to have mitogenic and metabolic ... IGF-II are mediated by binding to target cell ... Type II IGF receptor, a monomeric protein which ...
... (PAPP-A) is a large placenta-derived glycoprotein ... concentrations by placental trophoblast cells, and ... in increasing concentrations throughout gestation until ... to pregnancy since measurable levels have ...
Medicine Products: